July 29, 2005 Biotech traded lower all day on Friday in a low-volume, low-volatility session, redolent of a summer Friday afternoon, which it was. The Centient Biotech 200 was off more than 17 points at 3732.56, a loss of .47%. The stem cell sector (particularly StemCells) did well after Majority Leader Frist endorsed the stem cell bill currently in the Senate, Indevus licensed a hypogonadism drug from Schering, Idenix said its hepatitis B virus passed a Phase III trial, Genzyme submitted an application for its Pompe disease drug, American Pharma said a supplier problem would delay an injectible antibiotic, Takeda won fast-track for a sepsis drug, and Advanced Life Sciences lowered the proposed price of its IPO. More details...
